Get the Stockscreener App
1,038.40
0.53%
5.43
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $1,038.40, with a volume of 3.84M.
It is up +0.53% in the last 24 hours and down -1.51% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$1,032.97
Open:
$1024.43
24h Volume:
3.84M
Relative Volume:
1.11
Market Cap:
$929.39B
Revenue:
$59.42B
Net Income/Loss:
$18.41B
P/E Ratio:
51.36
EPS:
20.2197
Net Cash Flow:
$6.44B
1W Performance:
-2.37%
1M Performance:
-1.51%
6M Performance:
+31.48%
1Y Performance:
+37.06%
1-Day Range:
$1,018.00
$1,049.94
1-Week Range:
$1,012.57
$1,090.22
52-Week Range:
$623.78
$1,133.95
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,038.40 | 924.53B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
218.66 | 529.01B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
214.35 | 383.08B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVO
Novo Nordisk Adr
|
62.33 | 253.81B | 46.69B | 15.29B | 9.25B | 3.4329 |
|
NVS
Novartis Ag Adr
|
144.34 | 274.68B | 54.45B | 14.42B | 17.15B | 7.333 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-16-25 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-15-25 | Reiterated | BofA Securities | Buy |
| Dec-15-25 | Reiterated | Goldman | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Compounder sues Lilly and Novo for suppressing GLP-1RA competition - Pharmaceutical Technology
Eli Lilly's Taltz and Zepbound Combo Delivers Superior Results in Landmark Psoriatic Arthritis Trial - Finviz
Eli Lilly price tries to recoup some lossesForecast today19-01-2026 - Economies.com
Eli Lilly vs. Novo Nordisk: Which Stock Offers More Upside? - CoinCentral
OpenAI Backed Chai Discovery Partners With Eli Lilly to Accelerate Biologics Discovery - AIM Media House
Chai Discovery Strikes Eli Lilly AI Drug Deal - findarticles.com
Eli Lilly's Weight Loss Portfolio Generates $10 Billion in Quarterly Revenue - Intellectia AI
Prediction: 2026 Will Be the Year of Eli Lilly - The Motley Fool
Eli Lilly Faces Regulatory Delay for Weight-Loss Drug Candidate - AD HOC NEWS
What Eli Lilly (LLY)'s NVIDIA AI Lab And Obesity Data Reveal About Its Obesity Leadership Narrative - Yahoo Finance UK
The Truth About Eli Lilly (NYSEreplacing with LPLA): Why Everyone Is Suddenly Watching This Stock - AD HOC NEWS
Notable healthcare headlines for the week: Eli Lilly, UnitedHealth, and Boston Scientific in focus - MSN
Could Acquiring Ventyx Biosciences Send Eli Lilly Stock Soaring in 2026? - The Motley Fool
Eli Lilly Shares Face Pressure Following Regulatory Setback - AD HOC NEWS
Eli Lilly stock price in focus as FDA slips obesity pill deadline — what to watch in LLY next week - TechStock²
This pharmaceutical executive has Trump's ear - Politico
BMO Reaffirms Eli Lilly and Company (LLY) as an Obesity Market Leader - Finviz
Eli Lilly’s Strategic Moves in the Weight-Loss Drug Arena - AD HOC NEWS
Eli Lilly Partners with Nvidia to Invest $1 Billion in AI Drug Discovery - Intellectia AI
Eli Lilly: A Strong Player in the Pharmaceutical Arena - The Motley Fool
Eli Lilly stock: FDA pushes orforglipron decision to April 10 as lawsuit adds another overhang - TechStock²
Stock Quote & Chart | Eli Lilly and Company - Eli Lilly
Chai Discovery and Eli Lilly Partner to Accelerate AI-Driven Drug Development - Букви
From OpenAI’s offices to a deal with Eli Lilly — how Chai Discovery became one of the flashiest names in AI drug development - TechCrunch
Eli Lilly vs. Novo Nordisk: Which Is the Better Stock Buy? - The Motley Fool
Novo's Wegovy pill makes encouraging start in weight-loss race vs Lilly - Reuters
Continuous Bioprocessing Market Set to Surpass Valuation of US$ 2,331.98 Million By 2035 | Astute Analytica - GlobeNewswire Inc.
LLY Stock Falls After FDA Reportedly Delays Obesity Drug Ruling - Yahoo Finance
Nvidia and Eli Lilly Are Partnering on a $1 Billion Lab. Here's What Investors Need to Know. - The Motley Fool
NVIDIA and Lilly launch $1B AI lab for drug discovery ... - eeNews Europe
BofA Securities Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Cuts Target Price to $1,265 - 富途牛牛
Rakuten Securities Inc. Boosts Stock Position in Eli Lilly and Company $LLY - MarketBeat
OVERSEA CHINESE BANKING Corp Ltd Has $15.61 Million Stock Holdings in Eli Lilly and Company $LLY - MarketBeat
NVIDIA and Eli Lilly Launch AI Co-Innovation Lab for Drug Development - HLTH
Eli Lilly stock slides premarket after FDA sets April 10 target for weight-loss pill decision, GLP-1 lawsuit filed - TechStock²
Forbes J M & Co. LLP Acquires 3,186 Shares of Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company $LLY Holdings Reduced by Fjarde AP Fonden Fourth Swedish National Pension Fund - MarketBeat
Blalock Williams LLC Buys New Position in Eli Lilly and Company $LLY - MarketBeat
[JPM 2026] ABL Bio seeks next license-out after GSK, Eli Lilly deals - theinvestor.co.kr
Regulatory Hurdles and Legal Challenge Weigh on Eli Lilly Shares - AD HOC NEWS
Eli Lilly stock slides after FDA pushes obesity pill decision to April 10 - TechStock²
Lobbying Update: $2,200,000 of ELI LILLY AND COMPANY lobbying was just disclosed - Quiver Quantitative
IU and Eli Lilly team up to study impact of GLP-1 drugs in workplace - WRTV
Eli Lilly and Novo Nordisk Accused of Blocking Access to Lower-Cost Weight-Loss Drugs - PYMNTS.com
Eli Lilly Stock Slips After Antitrust Lawsuit Against GLP-1 Providers - Benzinga
Why Eli Lilly (LLY) Stock Is Down Today - Finviz
Eli Lilly (LLY) Faces Potential Delay in Weight Loss Pill Approval - GuruFocus
Disc Medicine, Sanofi, Eli Lilly Shares Slip On Reports Of FDA Increasing Review Time For Drugs Granted Priority Review Vouchers - Stocktwits
Eli Lilly drops as FDA decision on weight loss pill is now expected in April - Seeking Alpha
JPM: NVIDIA and Eli Lilly announce co-innovation AI lab - MobiHealthNews
Where is Eli Lilly and Company (LLY) Headed According to Analysts? - Insider Monkey
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.41%
9.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):